Skip to main content
. 2023 Jun 10;102(8):2137–2151. doi: 10.1007/s00277-023-05278-3

Fig. 2.

Fig. 2

PFS distributions with 95% confidence intervals in patients receiving IXA-Rd in L2 and L3 according to prior exposure to lenalidomide